Abstract
Drug metabolism in humans is essentially performed by three cytochrome P450 (P450) families (1 to 3), including 23 isoforms. The expression of these P450s is highly variable, and the rate and nature of the metabolites produced depend on the nature and the concentration of individual isoforms. P450 expression pattern is therefore a necessary tool to evaluate the effects of a given drug on P450 expression, its potential toxicity, and eventual interference with other drugs administered concomitantly. This pattern provides a general outline of the induction/repression effects of drugs leading to further mechanistic studies. A real-time quantitative reverse transcription-polymerase chain reaction (RT-PCR) assay was developed to evaluate the overall P450 expression pattern and measure human CYP1 to CYP3 mRNAs involved in drug metabolism. Our RT-PCR-based P450 mRNA assay enables us to quantify P450s rapidly with high specificity, a single annealing temperature, and low amounts of biological sample. All 23 single assays were validated by assessing the effects (induction or repression) of known inducers (ethanol, 3-methylcholanthrene, rifampicin, dexamethasone, phenobarbital) on P450 expression in human primary hepatocytes. Since this method may be used to determine human P450 expression in any human tissue or cell culture, it is a valuable tool for reliable prediction of drug safety, drug toxicity, and drug-drug interference.
Footnotes
-
This work was supported by the Institut National de la Santé et de la Recherche Médicale, the University Paris 5 René Descartes, the Ligue Nationale contre le Cancer and its Comité Régional des Hauts-de-Seine, and the Association de Recherches contre le Cancer.
-
Article, publication date, and citation information can be found at http://dmd.aspetjournals.org.
-
doi:10.1124/dmd.105.005173.
-
ABBREVIATIONS: P450, cytochrome P450; RT-PCR, reverse transcriptase-polymerase chain reaction; LT, long-term; EtOH, ethanol; 3-MC, 3-methylcholanthrene; RIF, rifampicin; DEXA, dexamethasone; PB, phenobarbital; DMSO, dimethyl sulfoxide; TBP, TATA box-binding protein; NCYP, N-fold differences in P450 gene expression relative to the TBP gene; PPIA, peptidylprolyl isomerase A; RPLP0, ribosomal protein P0.
- Received April 13, 2005.
- Accepted August 15, 2005.
- The American Society for Pharmacology and Experimental Therapeutics
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|